NASDAQ:CLVSClovis Oncology Stock Price, Forecast & News

$6.48

-0.20 (-2.99 %)

(As of 06/4/2020 04:00 PM ET)

Add

Compare

Today's Range

$6.43

Now: $6.48▼

$6.84

50-Day Range

$6.68

MA: $8.08▼

$9.69

52-Week Range

$2.93

Now: $6.48▼

$17.37

Volume6.15 million shs

Average Volume7.76 million shs

Market Capitalization$498.32 million

P/E RatioN/A

Dividend YieldN/A

Beta2.52

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Beat the Market (BTM) Rank^™

4.1 Analyst's Opinion

Consensus Rating
Clovis Oncology has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 5 buy ratings, 5 hold ratings, and 2 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.14, Clovis Oncology has a potential upside of 133.7% from its current price of $6.48.
Amount of Analyst Coverage
Clovis Oncology has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.5 Community Rank

Outperform Votes
Clovis Oncology has received 566 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Clovis Oncology has received 550 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Clovis Oncology has received 50.72% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote “Outperform” if you believe CLVS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CLVS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Clovis Oncology does not currently pay a dividend.
Dividend Growth
Clovis Oncology does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Clovis Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,445.00 in company stock.
Percentage Held by Insiders
Only 8.30% of the stock of Clovis Oncology is held by insiders.
Percentage Held by Institutions
44.23% of the stock of Clovis Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Clovis Oncology are expected to grow in the coming year, from ($4.22) to ($2.59) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Clovis Oncology is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Clovis Oncology is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Overall Beat the Market Rank^™

1.65 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:CLVS

Previous Symbol

CUSIP18946410

CIK1466301

Webwww.clovisoncology.com

Phone303-625-5000

Debt

Debt-to-Equity RatioN/A

Current Ratio2.47

Quick Ratio2.22

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$143.01 million

Price / Sales3.48

Cash FlowN/A

Price / Cash FlowN/A

Book Value($3.17) per share

Price / Book-2.04

Profitability

EPS (Most Recent Fiscal Year)($7.60)

Net Income$-400,420,000.00

Net Margins-271.13%

Return on Equity-1,576.32%

Return on Assets-62.01%

Miscellaneous

EmployeesN/A

Outstanding Shares76,901,000

Market Cap$498.32 million

Next Earnings Date8/6/2020 (Estimated)

OptionableOptionable

Receive CLVS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLVS and its competitors with MarketBeat's FREE daily newsletter.

Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions

How has Clovis Oncology's stock been impacted by COVID-19 (Coronavirus)?

Clovis Oncology's stock was trading at $6.17 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CLVS shares have increased by 5.0% and is now trading at $6.48. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Clovis Oncology?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 2 sell ratings, 5 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Clovis Oncology.

When is Clovis Oncology's next earnings date?

Clovis Oncology is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Clovis Oncology.

How were Clovis Oncology's earnings last quarter?

Clovis Oncology (NASDAQ:CLVS) released its quarterly earnings data on Tuesday, May, 5th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($1.28). The biopharmaceutical company earned $42.56 million during the quarter, compared to analyst estimates of $41.80 million. Clovis Oncology had a negative return on equity of 1,576.32% and a negative net margin of 271.13%. View Clovis Oncology's earnings history.

What price target have analysts set for CLVS?

12 brokers have issued 1-year price objectives for Clovis Oncology's shares. Their forecasts range from $4.00 to $36.00. On average, they expect Clovis Oncology's stock price to reach $15.14 in the next year. This suggests a possible upside of 133.7% from the stock's current price. View analysts' price targets for Clovis Oncology.

What are Wall Street analysts saying about Clovis Oncology stock?

Here are some recent quotes from research analysts about Clovis Oncology stock:

1. According to Zacks Investment Research, "Clovis reported mixed fourth-quarter results, wherein earnings missed estimates but revenues beat the same. Market share of Clovis’ Rubraca in the ovarian cancer PARP inhibitor market improved in 2019. Approval in second-line maintenance setting for ovarian cancer irrespective of the BRCA-mutation is boosting revenues. Successful development of Rubraca in several ongoing studies, targeting different types of ovarian cancer patients and potential approval for prostate cancer indication are likely to boost the drug’s prospects. The company is actively working on expanding the label of Rubraca. However, Rubraca faces strong competition from other PARP inhibitors in the market, Lynparza and Zejula. Moreover, competition is likely to increase with several others under development. Shares have underperformed the industry in the past year." (4/8/2020)
2. HC Wainwright analysts commented, "Our $36 price target is derived from a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for Rubraca in ovarian cancer combination and prostate cancer indications, and the net present value (NPV) for the current commercial business." (7/3/2019)

Has Clovis Oncology been receiving favorable news coverage?

Media headlines about CLVS stock have trended negative this week, InfoTrie reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Clovis Oncology earned a daily sentiment score of -2.7 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutClovis Oncology.

Who are some of Clovis Oncology's key competitors?

Some companies that are related to Clovis Oncology include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

What other stocks do shareholders of Clovis Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), Amarin (AMRN), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Intercept Pharmaceuticals (ICPT), Bristol-Myers Squibb (BMY), Alibaba Group (BABA) and Exelixis (EXEL).

Who are Clovis Oncology's key executives?

Clovis Oncology's management team includes the following people:

Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)
Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

Who are Clovis Oncology's major shareholders?

Clovis Oncology's stock is owned by many different institutional and retail investors. Top institutional investors include State Street Corp (4.77%), Geode Capital Management LLC (1.19%), Pinnacle Associates Ltd. (1.09%), SG Americas Securities LLC (0.82%), Sector Gamma AS (0.49%) and Nuveen Asset Management LLC (0.45%). Company insiders that own Clovis Oncology stock include Daniel W Muehl, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe, Patrick J Mahaffy, Paul Edward Gross and Thorlef Spickschen. View institutional ownership trends for Clovis Oncology.

Which major investors are selling Clovis Oncology stock?

CLVS stock was sold by a variety of institutional investors in the last quarter, including Soros Fund Management LLC, Rafferty Asset Management LLC, Spark Investment Management LLC, Fisher Asset Management LLC, Sector Gamma AS, Squarepoint Ops LLC, Weiss Multi Strategy Advisers LLC, and New York State Common Retirement Fund. Company insiders that have sold Clovis Oncology company stock in the last year include Daniel W Muehl, Gillian C Ivers-Read, Lindsey Rolfe, and Paul Edward Gross. View insider buying and selling activity for Clovis Oncology.

Which major investors are buying Clovis Oncology stock?

CLVS stock was acquired by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, BNP Paribas Arbitrage SA, Pinnacle Associates Ltd., Geode Capital Management LLC, Quantitative Investment Management LLC, Redmile Group LLC, Bank of New York Mellon Corp, and Quilter Plc. Company insiders that have bought Clovis Oncology stock in the last two years include James C Blair, Patrick J Mahaffy, and Thorlef Spickschen. View insider buying and selling activity for Clovis Oncology.

How do I buy shares of Clovis Oncology?

Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Clovis Oncology's stock price today?

One share of CLVS stock can currently be purchased for approximately $6.48.

How big of a company is Clovis Oncology?

Clovis Oncology has a market capitalization of $498.32 million and generates $143.01 million in revenue each year. The biopharmaceutical company earns $-400,420,000.00 in net income (profit) each year or ($7.60) on an earnings per share basis.

What is Clovis Oncology's official website?

The official website for Clovis Oncology is www.clovisoncology.com.

How can I contact Clovis Oncology?

Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff